Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.63 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.63 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870044 | 1.00 | ANPEP (0.80) | ANPEPKMT2AMEN1TSHRPSMB1 | |
| SCHEMBL5870605 | 0.88 | ANPEP (0.74) | ANPEPKMT2AMEN1TSHRPSMB1 | |
| SCHEMBL4770866 | 0.85 | ANPEP (0.79) | ANPEPPSMB5ALDH1A1LMNAMAPT | |
| SCHEMBL4770883 | 0.85 | ANPEP (0.79) | ANPEPPSMB5ALDH1A1LMNAMAPT | |
| SCHEMBL13700588 | 0.81 | FOLH1 (0.78) | KMT2AMEN1ALDH1A1LMNAMME | |
| SCHEMBL13559325 | 0.80 | NAALAD2 (0.68) | ANPEPKMT2AMEN1TSHR | |
| SCHEMBL13559296 | 0.80 | NAALAD2 (0.68) | ANPEPKMT2AMEN1TSHR | |
| SCHEMBL7272374 | 0.79 | MME (0.58) | ANPEPMME | |
| SCHEMBL8078351 | 0.79 | MME (0.58) | ANPEPMME | |
| Levacetylleucine SCHEMBL8973550 | 0.79 | ALDH1A1 (0.56) | ANPEPKMT2AMEN1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ANPEP 118/4885KMT2A 1880/4885MEN1 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.